Barely Significant
← all excerpts

Efficacy, safety, and correlative biomarkers of bintrafusp alfa in recurrent or metastatic nasopharyngeal cancer patients: a phase II clinical trial.

Lancet Reg Health West Pac · 2023 · PMC10493598 · PMID 37701718

Europe PMCDOI
1
hedged sentence
0.0200
closest p · 0.4× alpha
0.0200
boldest claim

The sentences

a decreasing trendP = 0.02actually significant
Patients who demonstrated a decreasing trend in EBV DNA during the first 4 weeks of treatment were associated with significantly better ORR (40% versus 6.3%, P = 0.02) and PFS ( Supplementary Fig.

also in 29,529 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.